Focus Partners Advisor Solutions LLC Trims Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Focus Partners Advisor Solutions LLC reduced its stake in Bristol-Myers Squibb (NYSE:BMY) by 39.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 27,054 shares of the biopharmaceutical company’s stock after selling 17,359 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Bristol-Myers Squibb were worth $1,530,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of BMY. Fairway Wealth LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Transce3nd LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. Comprehensive Financial Planning Inc. PA acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $34,000. Tacita Capital Inc purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $39,000. Finally, M Holdings Securities Inc. acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $39,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the firm’s stock in a transaction dated Friday, April 25th. The shares were acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.07% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Argus raised Bristol-Myers Squibb to a “hold” rating in a report on Friday, April 25th. Citigroup raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Friday, February 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Finally, Jefferies Financial Group reduced their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $46.99 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The business has a fifty day moving average of $52.05 and a 200-day moving average of $55.77. The stock has a market cap of $95.63 billion, a price-to-earnings ratio of -10.63, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the company posted ($4.40) EPS. The firm’s revenue for the quarter was down 5.6% on a year-over-year basis. As a group, analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were given a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.28%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.